3.5 Normal cardiac function: No history of angina, myocardial 
infarction, CHF. LVEF must be >40%. Exercise treadmill test 
must be normal. 
3.6. Creatinine clearance 50cc/min, bilirubin ^.1.5., SGOT ^2x 
normal, normal PT, PTT, calcium. 
3.7 Negative HIV serology and hepatitis B surface antigen. 
3.8 Adequate pulmonary function: DLCO >50% compensated for 
Hemoglobin; FEV >55%, PO 2 >60mm Hg. 
3.9 Histologically negative bilateral bone marrow biopsies prior to 
bone marrow harvest. 
3.10 No evidence of metastatic disease to the pelvis on plain film 
or bone scan. No prior pelvic radiation therapy. 3 sites of 
metastatic disease on bone scan. 
3.11 ECOG performance status 0, 1, 2 and a life expectancy >60 
days. 
3.12 Negative B-HCG serum pregnancy test in patients of child- 
bearing age. 
3.13 Ability to give informed consent. 
3.14 Good psychiatric and medical risk. All patients will undergo a 
psychosocial evaluation by the breast cancer psychiatric 
socia l . worker, 
4.0 Pretreatment Evaluation 
4.1 Complete history and physical examination with measurement 
of all palpable peripheral lymph nodes, liver, and other 
measurable lesions. 
Recombinant DNA Research, Volume 16 
[103] 
